Table 1 Baseline characteristics of patients of mITTa population.
Characteristics | Propolis (n = 98) | Placebo (n = 90) | Total (n = 188) |
|---|---|---|---|
Sex, Male | 54/98 (55.1%) | 64/90 (71.1%) | 118/188 (62.8%) |
Age, years, mean ± SD | 47.9 ± 12.5 | 46.7 ± 12.4 | 47.3 ± 12.4 |
Vaccinated for COVID 19 | 20/98 (20.4%) | 21/90 (23.3%) | 41/187 (21.9%) |
Clinical presentation | |||
Oxygen support | |||
None | 66/98 (67.3%) | 58/90 (64.4%) | 124/188 (66.0%) |
O2 catheter ˂ 5L/min | 27/98 (27.6%) | 26/90 (28.9%) | 53/188 (28.2%) |
O2 catheter ≥ 5L/min, high-flow or NIV | 5/98 (5.1%) | 6/90 (6.7%) | 11/188 (5.9%) |
Tomography results | |||
Clean image | 3/97 (3.1%) | 1/90 (1.1%) | 4/187 (2.1%) |
< 25% | 12/97 (12.4%) | 11/90 (12.2%) | 23/187 (12.3%) |
25–50% | 63/97 (64.9%) | 62/90 (68.9%) | 125/187 (66.8%) |
50–75% | 19/97 (19.6%) | 16/90 (17.8%) | 35/187 (18.7%) |
Temperature, ºC | 36.5 ± 1.1 | 36.5 ± 1.1 | 36.5 ± 1.1 |
SpO2 on admission < 93% | 12/97 (12.4%) | 10/89 (11.2%) | 22/186 (11.8%) |
RR on admission > 24 irpm | 4/97 (4.1%) | 6/90 (6.7%) | 10/187 (5.3%) |
SBP < 90 mmHg | 2/94 (2.1%) | 0/83 (0.0%) | 2/177 (1.1%) |
Randomization in ICU | 26/94 (27.7%) | 25/83 (30.1%) | 51/177 (28.8%) |
Comorbidities | |||
Diabetes | 8/98 (8.2%) | 10/90 (11.1%) | 18/188 (9.6%) |
Hypertension | 26/98 (26.5%) | 22/90 (24.4%) | 48/188 (25.5%) |
COPD | 1/98 (1.0%) | 5/90 (5.6%) | 6/188 (3.2%) |
Obesity | 12/98 (12.2%) | 12/90 (13.3%) | 24/188 (12.8%) |
Stroke | 0/98 (0.0%) | 0/90 (0.0%) | 0/188 (0.0%) |
Myocardial infarction | 1/98 (1.0%) | 0/90 (0.0%) | 1/188 (0.5%) |
Baseline treatment | |||
Antibiotics | 63/97 (64.9%) | 63/90 (70.0%) | 126/187 (67.4%) |
Tamiflu | 0/97 (0.0%) | 1/90 (1.1%) | 1/187 (0.5%) |
Hydroxychloroquine | 3/97 (3.1%) | 2/90 (2.2%) | 5/187 (2.7%) |
Corticosteroids | 82/97 (84.5%) | 83/90 (92.2%) | 165/187 (88.2%) |
Tocilizumab | 2/97 (2.1%) | 5/89 (5.6%) | 7/186 (3.8%) |
Pentaglobin | 1/97 (1.0%) | 1/90 (1.1%) | 2/187 (1.1%) |
Remdesivir | 0/61 (0.0%) | 2/47 (4.3%) | 2/108 (1.9%) |
